Meeting
2011 ASCO Annual Meeting
AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
Authors
O. L. Chinot
University Hospital Timone, Marseille, France
O. L. Chinot , W. Wick , F. Saran , W. P. Mason , R. Henriksson , R. Nishikawa , A. H. Zeaiter , N. Moore , A. Das , T. F. Cloughesy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00943826
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS136)
Abstract #
TPS136
Poster Bd #
40F
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM).
First Author: Ryo Nishikawa
Poster
2020 ASCO Virtual Scientific Program
Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.
First Author: Wenyin Shi
Poster
2019 ASCO Annual Meeting
Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).
First Author: Hao-Wen Sim
Poster
2019 ASCO Annual Meeting
EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.
First Author: Patrick Roth